The trials and hopes for drug development in sickle cell disease

Kenneth Ataga, Jonathan Stocker

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Although sickle cell disease (SCD) is highly prevalent worldwide, it is a rare disease in the United States and Europe. Over the past decade, there has been an increased understanding of the pathophysiology of SCD. While multiple drugs have been tested, only one drug, hydroxycarbamide, is approved by the relevant regulatory agencies specifically for this disease. Due to the combination of an improved understanding of disease pathophysiology, governmental support and the success of several recently approved drugs for other orphan diseases, there is an increased interest in the development of targeted drugs for SCD. Novel drugs that are currently being evaluated include haemoglobin F inducers, anti-sickling agents, anti-oxidants, anti-adhesive agents, anti-inflammatory agents, anticoagulants and anti-platelet agents. In addition to the evaluation of acute pain crisis as a study endpoint, clinical trials employing other SCD-related complications, exercise capacity, as well as patient reported outcomes are warranted and necessary in order to advance the development of these novel therapeutic agents. Finally, despite the availability of multiple biomarkers, many of these are of limited clinical value in SCD and require further assessment in prospective studies to validate their prognostic importance before they are acceptable as surrogate endpoints.

Original languageEnglish (US)
Pages (from-to)768-780
Number of pages13
JournalBritish Journal of Haematology
Volume170
Issue number6
DOIs
StatePublished - Sep 1 2015

Fingerprint

Sickle Cell Anemia
Pharmaceutical Preparations
Rare Diseases
Biomarkers
Fetal Hemoglobin
Acute Pain
Oxidants
Adhesives
Anticoagulants
Anti-Inflammatory Agents
Blood Platelets
Clinical Trials
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

The trials and hopes for drug development in sickle cell disease. / Ataga, Kenneth; Stocker, Jonathan.

In: British Journal of Haematology, Vol. 170, No. 6, 01.09.2015, p. 768-780.

Research output: Contribution to journalReview article

@article{d9647a04274e462b8c0994053b0fa031,
title = "The trials and hopes for drug development in sickle cell disease",
abstract = "Although sickle cell disease (SCD) is highly prevalent worldwide, it is a rare disease in the United States and Europe. Over the past decade, there has been an increased understanding of the pathophysiology of SCD. While multiple drugs have been tested, only one drug, hydroxycarbamide, is approved by the relevant regulatory agencies specifically for this disease. Due to the combination of an improved understanding of disease pathophysiology, governmental support and the success of several recently approved drugs for other orphan diseases, there is an increased interest in the development of targeted drugs for SCD. Novel drugs that are currently being evaluated include haemoglobin F inducers, anti-sickling agents, anti-oxidants, anti-adhesive agents, anti-inflammatory agents, anticoagulants and anti-platelet agents. In addition to the evaluation of acute pain crisis as a study endpoint, clinical trials employing other SCD-related complications, exercise capacity, as well as patient reported outcomes are warranted and necessary in order to advance the development of these novel therapeutic agents. Finally, despite the availability of multiple biomarkers, many of these are of limited clinical value in SCD and require further assessment in prospective studies to validate their prognostic importance before they are acceptable as surrogate endpoints.",
author = "Kenneth Ataga and Jonathan Stocker",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/bjh.13548",
language = "English (US)",
volume = "170",
pages = "768--780",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The trials and hopes for drug development in sickle cell disease

AU - Ataga, Kenneth

AU - Stocker, Jonathan

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Although sickle cell disease (SCD) is highly prevalent worldwide, it is a rare disease in the United States and Europe. Over the past decade, there has been an increased understanding of the pathophysiology of SCD. While multiple drugs have been tested, only one drug, hydroxycarbamide, is approved by the relevant regulatory agencies specifically for this disease. Due to the combination of an improved understanding of disease pathophysiology, governmental support and the success of several recently approved drugs for other orphan diseases, there is an increased interest in the development of targeted drugs for SCD. Novel drugs that are currently being evaluated include haemoglobin F inducers, anti-sickling agents, anti-oxidants, anti-adhesive agents, anti-inflammatory agents, anticoagulants and anti-platelet agents. In addition to the evaluation of acute pain crisis as a study endpoint, clinical trials employing other SCD-related complications, exercise capacity, as well as patient reported outcomes are warranted and necessary in order to advance the development of these novel therapeutic agents. Finally, despite the availability of multiple biomarkers, many of these are of limited clinical value in SCD and require further assessment in prospective studies to validate their prognostic importance before they are acceptable as surrogate endpoints.

AB - Although sickle cell disease (SCD) is highly prevalent worldwide, it is a rare disease in the United States and Europe. Over the past decade, there has been an increased understanding of the pathophysiology of SCD. While multiple drugs have been tested, only one drug, hydroxycarbamide, is approved by the relevant regulatory agencies specifically for this disease. Due to the combination of an improved understanding of disease pathophysiology, governmental support and the success of several recently approved drugs for other orphan diseases, there is an increased interest in the development of targeted drugs for SCD. Novel drugs that are currently being evaluated include haemoglobin F inducers, anti-sickling agents, anti-oxidants, anti-adhesive agents, anti-inflammatory agents, anticoagulants and anti-platelet agents. In addition to the evaluation of acute pain crisis as a study endpoint, clinical trials employing other SCD-related complications, exercise capacity, as well as patient reported outcomes are warranted and necessary in order to advance the development of these novel therapeutic agents. Finally, despite the availability of multiple biomarkers, many of these are of limited clinical value in SCD and require further assessment in prospective studies to validate their prognostic importance before they are acceptable as surrogate endpoints.

UR - http://www.scopus.com/inward/record.url?scp=84940604404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940604404&partnerID=8YFLogxK

U2 - 10.1111/bjh.13548

DO - 10.1111/bjh.13548

M3 - Review article

VL - 170

SP - 768

EP - 780

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -